Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

NetLinkz - Voluntary Suspension (ASX:NET)

The securities of Netlinkz Limited (‘NET’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of NET, pending the release of an announcement regarding a...read more

Noxopharm Announces COVID-19 Trial Program to Commence in Europe (ASX:NOX)

NOX announces commencement of its NOXCOVID clinical program with a planned Phase 1 trial in Europe. This action is designed to provide important safety data and proof-of-principle of Veyonda as a po...read more

NetLinkz Announces Trading Halt (ASX:NET)

The securities of Netlinkz Limited (‘NET’) will be placed in trading halt at the request of NET, pending it releasing an announcement regarding a capital raising. Unless ASX decides othe...read more

NetLinkz - S&P DJI Announces June 2020 Quarterly Rebalance (ASX:NET)

S&P Dow Jones Indices announced today the changes in the S&P/ASX indices, effective at the open of trading on June 22, 2020. At this rebalance, the entire S&P/ASX index hierarchy is revi...read more

Noxopharm Announces ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer (ASX:NOX)

Noxopharm (ASX: NOX) today reports on the public release at a global oncology conference of 2 sets of clinical data relating to the development of NOX66 (Veyonda®) as a treatment of end-stage ca...read more

NetLinkz - Pause in trading (ASX:NET)

Trading in the securities of the entity will be temporarily paused pending a further announcement. For more information, download the attached PDF.

Milestone Achieved in the Nyrada Brain Injury Program (ASX:NYR)

Nyrada Inc (ASX: NYR) provides an update on one of its leading programs for treatment of brain injury. Nyrada has shown in a preclinical pharmacokinetic study that its lead candidate compounds ca...read more

Noxopharm announces FDA allows Veyonda Pre-IND Submission for COVID-19 (ASX:NOX)

Noxopharm (ASX:NOX) today announces that on advice from the U.S. Food and Drug Administration (FDA), the Company has lodged a pre-Investigational New Drug (pre-IND) submission for a clinical trial o...read more

Noxopharm - $7.9 Million Fully Underwritten Entitlement Offer Announced (ASX:NOX)

Noxopharm (ASX: NOX) today announces it will undertake a 1 for 2.5 fully underwritten, pro-rata entitlement offer (“Entitlement Offer”) of new fully paid ordinary shares in the Company (...read more

Noxopharm, Abscopal Responses Achieved in Prostate Cancer (ASX:NOX)

Noxopharm (ASX:NOX) today releases details of the radiographic review of its DARRT-1 clinical study and is pleased to report that it shows a major benefit from a combination of Veyonda® and low-...read more

Novatti Group, March 2020 Quarterly Update (ASX:NOV)

Novatti Group Limited (ASX:NOV) (Novatti or Company), a leading digital banking services and payments company, is pleased to provide an update for the March 2020 quarter. For further information,...read more

Novatti Group, Appendix 4C - quarterly (ASX:NOV)

For further information, please download the attached PDF:

Novatti Group, Record Quarter of Processing Revenue (ASX:NOV)

Novatti Group Limited (ASX:NOV) (Novatti or Company), a leading digital banking services and payments company, is pleased to provide an update on the performance of its processing business for the M...read more

Netlinkz - Appointment of Chief Financial Officer (ASX:NET)

NetLinkz Limited (‘NetLinkz’ or ‘the Company’) is pleased to announce that it has appointed Mathew Ryan as Chief Financial Officer effective Monday April 27, 2020. Mathew ...read more

Netlinkz - Appendix 4C - quarterly (ASX:NET)

NetLinkz Ltd (ASX:NET) is pleased to provide our quarterly Appendix 4C update of its activities and achievements for the March quarter, 2020. Highlights A$2.19m revenue generated at a Gro...read more

Viewing: 1 - 15 of 200 Previous | Next